Heart attack despite a healthy diet? Stroke without high blood pressure? The reason might lie in the blood–and few people ...

Anteris Technologies ( ($AU:AVR) ) has provided an update. Anteris Technologies has announced the issuance of 2,346,936 shares of Common Stock as ...

In ENCIRCLE, TMVR was performed in very ill patients with symptomatic mitral valve disease unsuitable for surgery or commercially available transcatheter edge-to-edge repair (TEER). Given the huge ...

Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...

Over the past few days, medtech's biggest names gathered in San Francisco for the Transcatheter Cardiovascular Therapies (TCT ...

In separate major multicenter trials, two novel valve systems proved effective in severe mitral valve diseases for which there are limited or no options.

Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart ...

Lp(a)] has emerged as a major, genetically determined risk factor in atherosclerotic cardiovascular disease (ASCVD) and ...

Anteris Technologies ( ($AU:AVR) ) just unveiled an update. Anteris Technologies has announced the successful treatment of the first patients in ...